Testosterone-transdermal TheraDerm LRS - Allergan

Drug Profile

Testosterone-transdermal TheraDerm LRS - Allergan

Alternative Names: Androderm; Androflex; Andropatch; Atmos

Latest Information Update: 15 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Watson Laboratories
  • Developer Endo International
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action DNA-directed RNA polymerase stimulants; Protein synthesis stimulants; Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypogonadism

Most Recent Events

  • 23 Jan 2015 Biomarkers information updated
  • 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
  • 21 Oct 2011 US FDA approves a lower-dose formulation of testosterone-transdermal TheraDerm LRS for Hypogonadism in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top